ROIV
Roivant Sciences Ltd
36.10$
-1.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -26.1% | -61.9% | +136.3% | +0.0% | -39.7% | -51.2% | -22.9% | -16.1% | -972.1% | – | -98.0% | – | |
| – | +10.2% | -14.0% | +53.4% | +0.0% | +16.8% | -0.2% | -1.6% | -0.4% | +28.3% | -26.5% | +8.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23.8% | -24.7% | -35.4% | +0.0% | -615.1% | – | -207.8% | – | +32.5% | -6,513.5% | – | – | |
| – | +29.1% | -1.7% | +185.4% | +0.0% | +83.4% | -55.6% | +397.5% | +94.5% | -37.1% | -74.4% | -66.8% | – | |
| – | – | -99.9% | -47,640.3% | +0.0% | – | +136.6% | -201.1% | – | +23.5% | -9.7% | +109.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | -147.7% | +0.0% | +129.5% | +21.4% | -29.5% | -100.0% | – | – | +85.9% | – | |
| – | – | – | – | – | +2,578.2% | -100.0% | – | – | – | – | – | – | |
| – | +13.8% | -113.8% | +234.3% | +0.0% | +150.2% | -35.1% | +6.0% | – | +361.7% | -110.2% | +1,214.9% | – | |
| – | – | -103.4% | – | – | – | – | -304.0% | – | – | -123.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.